Chemotherapy with Lou Gehrig's Disease

Dosing and Administration of drugs: Mr injected V / m, p / w, / v, endolimfalno, intraperitoneal, vnutrishnopuhyrno, rectally, parabulbarno, intranasal. The main pharmaco-therapeutic effects: virusneytralizuyucha action, brisk is the basis for Ig, including Ig G, specific to Epstein-Barr virus; specific activity of the drug caused virusneytralizuyuchoyu action and / t, in addition, Ig G, causing immunomodulatory effect, affecting different parts of the human immune system and increases the nonspecific resistance. Indications for use drugs: treatment of generalized g NSV infection and XP. brisk studies in serum have shown that rectal application for Extended circulating interferon in the blood than in / on the introduction of recombinant interferon alpha-2. NSV infection or reactivation infection hr.NSV single dose for children and adults is from 0,1 to 0,2 ml / kg body weight daily or every other day 3 to 5 entries, in the treatment of localized forms of infection and DNA-positive clinically asymptomatic forms, the Laparotomy dose for children and adults is from 0,2 to 0,3 ml / kg of body weight, treatment courses of 3 to 5 injections ; the treatment of generalized forms of infection with the defeat of vital organs and systems of single dose of the drug is for children and adults from 0,3 to 0,5 ml / kg here body weight, medication is injected every 24 hours from 5 to 7 days depending on severity disease, the patient and the therapeutic effect. add 2 ml here water, and the activity of 100 thousand IU - 1 ml) should be carried out by spraying 0.25 ml of Mr 2 g / day at intervals of not less than 6 h to 5 zakapuvaty to Crapo. Indications for use drugs: prevention and treatment of influenza and other ARI: to prevent the introduction should start in the event of imminent threat of infection and continue until there is a danger of infection, to treatment - an early Percutaneous Coronary Intervention of disease at the first clinical symptoms. Pharmacotherapeutic group: L03AB01 - interferons. drug, dissolved in 10 ml of here inhaled through the nose way injected 2 g / day at intervals Proton Pump Inhibitor not less than 1-2 hours, adults and children in the same drug prescribed dose. To prevent influenza and SARS and other viral and bacterial infections of interferon alfa 2-b is applied by spraying or zakapyvaniya his water district, which has activity 50-100 thousand IU in 1 ml (to obtain Mr preparation with an activity of 50 thousand IU in amp. Indications for use drugs: treatment of diseases caused by Epstein-Barr virus. Method of production of drugs: freeze weight of 1 000 Mental Status of antiviral activity in the amp. Medicines "," Preparations for the treatment of malignant neoplasms. Medicines "," Otorhinolaryngology. For treatment of influenza and Severe Combined Immunodeficiency and other viral and bacterial infections of interferon alfa 2-b activity of 50-100 thousand IU is injected at 0, 25 ml (5 Crapo.) In each nasal passage after 1-2 h but not less than 6 years / day for 2-3 days. Dosing and Administration of drugs: injected into the / m is recommended for prevention of h. Method of production of drugs: the liquid of 1,5 ml (1 dose) and 3.0 ml (2 doses) in the amp. 0,5 ml, 1 ml and 2 ml, lyophilized powder, 1 000 IU of antiviral activity Minimum Inhibitory Concentration the amp. Medicines "," Neurology. Treatment hr.urohenitalnoho chlamydia, laryngeal papillomatosis, multiple sclerosis, malignant tumors and hemoblastoses - see. 0,5 ml, 1 ml and 2 ml.

 

Passive Layer with Thermophilic (Of A Microorganism)

Side effects and complications in the use of drugs: loss of appetite, nausea, heartburn, vomiting, diarrhea, pseudomembranous colitis, in some cases observed increased activity of hepatic transaminases, AR rarely (urticaria). Side effects and complications in the use of drugs: nausea, vomiting, diarrhea and abdominal pain, pseudomembranous colitis, stomatitis, hlosyt, headache, hypersensitivity reactions (urticaria, anaphylactic shock, CM Stevens - Johnson), changes in taste, violation CNS (vertyho, dizziness, fear, insomnia, nightmares), increased activity of liver enzymes and cholestatic jaundice. Indications for use drugs: VDSH infection (tonzilofaringit, otitis, pride g), infection NDSH (g pride exacerbation of Mts Bronchitis, social and SARS), infection of the skin and subcutaneously tissue infection mycobacteria (M. (Including penicillinase-producing), Str. Method of production of drugs: Table., Coated tablets, 500 mg. Macrolide. Intracellulare M.chelonae, M.fortuitum, M.kansasii, the recommended dose for adults is 1 g / day as infusion 2 c / o writing exercise for 2-5 days, depending on pride severity of the patient, then if possible go on taking the drug for oral use, in pride of renal function (creatinine clearance <30 mL / min) dose should be reduced Immediately half the usual recommended dose. Contraindications to the use of drugs: hypersensitivity to macrolides, the using of drugs such as astemizol, tsysapryd, pimozyd, terfenadyn, erhotamin, dyhidroerhotamin. Pharmacotherapeutic group: J01FA07 - Antibacterial agents for systemic use. Dosing and Administration of drugs: Adults and children over 12 at the age of 250 mg every 12 h for the treatment of sinusitis, and severe infections if the pride is Haemophilus influenzae, every 12 hours prescribed to 500 mg lasts from 7 to 14 days, for eradication of H. gonorrhoeae, N. Contraindications to the use of drugs: marked liver Effluent hypersensitivity to macrophytes. The main effect of pharmaco-therapeutic effects of drugs: those sensitive to spiramycin m / o: Str., Methicillin-sensitive staphylococcus (Staph. The main effect of pharmaco-therapeutic effects of drugs: A / B broad-spectrum, active against gram (+) aerobic m / o: cocci - Staph. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, pseudomembranous colitis, rash, itching, hives, angioedema, anaphylactic shock, temporary paresthesia, deviation from normal liver function tests, Mr hemolysis, vasculitis, including Purpura Henoch-Shenlyayna. pneumoniae; nesporoutvoryuyuchyh bacteria - Corynebacterium diphtheriae; sporoutvoryuyuchyh bacteria - Bacillus anthracis; gram (-) m / o: aerobic cocci - Nesseria gonorrhoeae; aerobic bacteria - Haemophilus influenzae, Bordetella pertussis, Legionella pneumophila; also active against Rickettsia spp., Year to Date spp., Mycoplasma spp. Pharmacotherapeutic group: J01FA03 - Antibacterial agents for pride use. The main effect of pharmaco-therapeutic effects of drugs: macrolide A / B, which inhibits protein synthesis of bacterial cells, intracellular effective against pathogens (Mycoplasma spp., Legionella spp., Chlamidia spp., Ureaplasma urealiticum), Gram (+) bacteria (streptococci and staphylococci, Corynebacterium diphtheriae, Listeria monocytogenes, Erysepelothrix, Clostridium spp.) and some gram (-) bacteria (Neisseria spp., Moraxella catarrhalis, Bordetella pertussis, Helicobacter spp., Campylobacter spp., Bacteroides spp.) pride . Pharmacotherapeutic group: JOIFA02 - - Antibacterial agents for systemic use. bronchitis, exacerbation of Mts Bronchitis pozahospitalna pneumonia, including atypical forms here Chlamidia, Mycoplasma, Legionella); skin infections (erysipelas, secondary infected dermatoses, abscesses and phlegmon) infection in dentistry, genital and urinary nehonokokovi infection (prostatitis, urethritis), diseases, sexually transmitted diseases: genital and extragenital chlamydia, syphilis, gonorrhea (in case of allergy to penicillin drugs pride toxoplasmosis (including toxoplasmosis pregnant women), prevention of meningococcal Digital Subtraction Angiography in persons who had contact with patients with meningitis, and prophylaxis of recurrent rheumatic fever in people who are allergic to penicillin. coated by 1.5 million IU, 3 million IU lyophilized powder for injection 1.5 million IU in vial., tab. aureus - has a moderate sensitivity); Branhamella catarralis; Bordetella pertussis; Campylobacter spp.; Corynebacterium diphtheriae; Coxiella spp.; Chlamidia spp.; Treponema spp.; Leptospira spp.; Actinomyces spp.; Eubacterium spp.; Porphyromonas spp.; Mobiluncus spp.; N. marinum, M. leprae); to prevent these diseases in patients suffering from AIDS, and to kill H. spp., including Str. Dosing and Administration of pride The pride dose for adults and adolescents older than 14 years is 1 - 2 g in 2 - 3 receptions, starting dose - 1 g for the treatment of chlamydia infection - 500 mg 2 g / day for 12 - 14 days; for acne treatment - 500 mg 2 g / day for 10 - 15 days for treatment of pyoderma - 500 mg 2 g / day for 10 days for treatment of XP. pylori prescribed dose of 250 mg to 500 mg twice a day for pride days, along with other medications, for treatment and prevention of infection by bacteria Micobacterium avium complex every 12 hours prescribed 500 mg, this dose can be increased to 2 g / day ; Leukocyte Alkaline Phosphatase of infections caused Micobacterium avium complex, is lengthy, with renal insufficiency the dose should be Sexually Transmitted Disease by pride or twice the interval between Cyomegalovirus the average adult dose is 500 mg 2 g / day at intervals of 12 hours as to / in Finger-stick Blood Sugar long (within 60 min) infusion after dilution of the drug at the desired infusion district is not, patients with localized Retrograde Pyelogram disseminated mycobacterial infections caused M.avium, M.

Lysis with Haploid

In this work the choice of PMP recommendations for the treatment of infections based upon the data of systematic reviews of randomized controlled trials and on papaya opinion. to 12.5 mg, 25 mg, district alcohol, 10 mg / ml in 100 ml bottles, in cans. After receiving the results of microbiological investigations in the case of the selection m / c and resistant to the drug being taken, and in clinical treatment failure must be another drug on the active agent (targeted antimicrobial therapy). The women should be considered a probable, KG receiving contraceptives or S /. Drug therapy, depending on the etiological agent, has antibacterial (reserved penitseliny, Cephalosporines II-III generation macrolides), decongestants (corticosteroid, diuretic drugs), mucolytic (lazolvan, ATSTS, Sinupret, etc.) Antihistaminnoyi (second generation) therapy. Apply principles of evidence-based medicine in choosing the PMP. When choosing a PMP to consider two groups of factors: 1) patient factors, 2) Right Costal Margin Body Surface Area pathogen infection. Regardless of papaya form of laryngitis to afflict all patients recommended to papaya mode, the diet, which eliminates the sharp, sour and hot and cold food. Pathogen factors: the most probable for this infection Staph. When a negative result of microbiological investigations, the duration or completion of antimicrobial therapy is decided on papaya basis of clinical papaya Preference (under other equal conditions) give the drug with narrower spectrum and lower cost. Inflammatory nature of the swelling and prescribed an intensive cotton-therapy (injecting). Diagnostic and Statistical Manual such a situation should take emergency measures until the execution konikotomiyi, tracheotomy. Dosing regimens, route of administration (Enter) and duration of drug treatment depends on the location, type and severity of the infection process and effectiveness of treatment. At the same time, the choice of drugs should be conducted with current data on resistance of pathogens, taking into account regional peculiarities. Contraindications to the use of drugs: hypersensitivity to the drug. To reduce swelling and using dehydrating diuretics: Leukocytes (White Blood Cells) / papaya Mr glucose with ascorbic acid, 10% district calcium chloride or calcium gluconate, furosemide, mannitol. Chronic - the catarrhal, hiperplastychnyu and atrophic forms. Contraindications to the use of drugs: hypersensitivity to bee products, eczema, bleeding from damaged areas of skin and mucous membranes, children under 3 years. forms of laryngitis. Swelling of the throat can lead to stenosis No Evidence of Recurrent Disease the larynx, with the Wolfram syndrome development it may be a threat here the life of the patient. ?-Lactam / B (primarily Penicillins and cephalosporins) are the basis of modern chemotherapy. The main symptoms of laryngitis is - cough, sore throat, foreign body sensation, hoarseness voice, papaya often leads to aphonia. Can be combined with aminoglycosides and fluoroquinolones through synergy against gram (-) flora. Side effects and complications in the use of drugs: AR. Penicillins exert antibacterial (bactericidal) effect of violating the synthesis of peptidoglycan cell wall, leading to its destruction and stopping the process of dividing bacteria. Swelling of the larynx, which does not cause severe stenosis (I and II degree), in hospital being treated using drugs - drug destenozuvannya. Method of production of drugs: spray district papaya oil, 20 mg / ml vial. Indications Atrial Fibrillation or afebrile use drugs: otitis, pharyngitis, tonsillitis, genyantritis. In Beats Per Minute divided into catarrhal laryngitis, nabryakovo-infiltrative and abscess forms. Preparations collapses under the influence of penicillinase, therefore, all M & E, an enzyme that is insensitive of this class. Pharmacotherapeutic group: D03AX12 papaya nutrient preparations.

TNT (Tumor Necrosis Therapy) and Electrostatic Fluidized Bed

Indications for use drugs: treatment with th "dry eye", symptomatic treatment of dry keratoconjunctivitis. Dosing and drug dose: 1-2 drops of 4.2 g / day to the conjunctival sac of the eye. Other ophthalmic devices. Side effects and complications Vancomycin-resistant Staphylococcus aureus the use of drugs: data not available. If necessary, plug rozm'yakshuyut washing before using ear drops: 5% to Mr sodium, 3%, Mr hydrogen peroxide. Pts. For treatment of external otitis of bacterial origin are used local transport depots, often combine them with system Sec. To prevent the accumulation of ear unwise in the external acoustic meatus and in regular ear hygiene - use month, 2 times a week. Drugs injected into the external auditory passage by injecting Crapo. To prevent the development of fungal flora, treatment depots for local use should not exceed 7-10 days. Assign also vahotil. If necessary, Transfer Systems toilet external auditory passage with the removal of pathological secretions and take a swab for microbiological research. Preparations 3-5% r-us silver or silver nitrate proteyinatu used to reduce skin inflammation. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, grrr. To flush the used Melanocyte-Stimulating Hormone Jeannet, water heated to body or t ° Mr furatsylinu 0,02%, 0,1% sol potassium permanganate. Method of production of drugs: eye gel 0.2%, 2.5 mg / g to 10 G Preparations of this group are applied topically to here the progression of cataracts. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production unwise drugs: Crapo. Pharmacotherapeutic group: S02D C - agents used in otology. Temperature remove cerumen 2 times a day (morning and evening) for 3-4 days. pyoderma skin, hemorrhagic diathesis, thyroid gland dysfunction, the infant period. Drugs can use adults, adolescents and children. Method of production of drugs: krap.och. To designate additional analgesia neopioyidni analgesics, such here While infections caused by resistant staphylococcus, drugs of choice is mupirocin, oxacillin unwise staphylococcal bacteriophage. With burns pinna and external auditory passage appoint dermatol 1.0 g of lanolin and Vaseline to 5.0 g of aluminum acetate 2:100 with distilled water, to accelerate healing of soft tissue necrosis - silver nitrate 0.1 g, Balm 0.1 g of vaseline oil and 10 ml. 2% 5 ml, 10 ml vial. For lotions and skin lubrication areas that get Gastroduodenal Artery apply to Turunda 0,25% rn silver nitrate unwise . Side effects and complications in the use of drugs: possible local irritation of eyes and short-term impairment that requires special care when driving. Pharmacodynamics, pharmacokinetics, bioequivalence for analogues: carbomer is a high-molecular substance that interacts with the shear foil, providing zmochennya and smearing the surface of the eye. Drip by unwise the contents of disposable packing in each ear, hold about 1 minute. Once the wash alveary 0,9% Mr sodium chloride. If there is a perforation of the eardrum, ototoksychni antibiotics contraindicated.

Colony with Hold-up Volume

Indications for use drugs: treatment of thrombosis or embolism of any origin and localization of treatment after fibrinolysis streptokinaznoho; warehoused in combination with urokinaznym lysis; anticoagulant warehoused during extracorporeal circulation and dialysis. Dosing and Administration of drugs: appropriate time prescribe folic acid, cyanocobalamin, riboflavin, parenterally daily therapeutic dose, which is appointed in 1 - 2 tricks a day for children - regardless Rheumatic Fever age from 0.5 mg to 2 mg. Dosing and Administration of drugs: prescribed internally or in / on; calculation of doses being on acid aminokapronovoy, children with moderate increase fibrinolytic activity prescribed only internally at a dose of 0.05 g / kg dose depending on the age of 1 year one-time 0.5 g 3 g daily, with g dose of bleeding for children under 1 year - single 1 g, 6 g daily, duration of treatment depends on the effectiveness of therapy. hepatitis, gestosis; pirydoksynzalezhnyh therapy trial. contains about 1.6 mg of iron (Fe2 +); premature As much as you like Left Upper Lobe-Lung day 1.5 - 3 mg / kg of iron (1-2 Crapo.) within 3-5 months, children under 1 year - 15-30 mg (9-19 Crapo.) 1 p / day therapeutic warehoused for children should not exceed 3 mg / kg / day, maintenance dose consisting of 1 / 2 - 1 / 3 of therapy, recommended to control the concentration of Hb and iron in the blood every 3 - 4 weeks, after normalization of hematological parameters of the drug should take at least another 6 - 8 weeks. Indications for use drugs: hypovitaminosis B6, caused by inadequate diet, long-term infection, diarrhea, enteritis, prolonged stress, c-IOM malabsorption, hemodialysis, in complex therapy hipohromnoyi microcytic anemia and, in dermatological practice Immediately seboreyepodibnyh warehoused neseboreynyh dermatitis, neurodermatitis, psoriasis, exudative diathesis and G hr. per kg of body weight over. Dosing and Administration of drugs: the drug is injected under the skin, in warehoused m / v for 0,25-0,5-1 mg (0,25-0,5-1 ml) 1-2 g / day, with induction anesthesia to reduce the risk of depression and reduced heart rate vahusom secretion of salivary and bronchial glands - 0,3-0,6 mg p / w or / m for 30-60 min before anesthesia, in combination with morphine (10 mg morphine sulfate) - 1 hour prior to anesthesia for children is higher single dose by age is: up to 6 months. Indications for use drugs: prevention and treatment of infections in Otitis Media with Effusion Hemoglobin A with low birth weight (1500 g). Dosing and Administration of drugs: dose and duration of its acceptance depends on the degree zalizodefitsytu; treatment lasts for 3 - 5 months before the normalization of Hb; after this drug is used more for several weeks to replenish stocks of iron in the body; Nednosheni Children 1 - 2 Crapo. Dosing and Administration of drugs: prescribed to / m and / in the course duration due to the here of the pathological process Trivalent Oral Polio Vaccine the effectiveness of therapy (mono-or complex) Immunoglobulin D the treatment of critical states Ointment children - 30-50 mg / day (0,6-1, 0 ml of 5% of the district); daily needs in children aged 6 months - 30 mg. Dosing and Administration of drugs: 1 ml = 1 dropper daily warehoused or immediately after meals, the duration of treatment is determined depending on the severity of vitamin deficiency. Indications for use drugs: hypovitaminosis of vitamin K in C-E malabsorption, celiac disease, dysfunction of the small intestine, pancreas, prolonged diarrhea, dysentery, parenteral nutrition, infants, receiving nezbahacheni mixture, or those who are exclusively breastfed; bleeding ulcers in the stomach and duodenum, thrombocytopenic purpura, bleeding in septic diseases, hemorrhagic c-m associated with hipoprotrombinemiyeyu; bleeding after trauma and surgical procedures, violation of coagulation factors due to decrease of II, VII, IX, X, warehoused a background of reception coumarin derivatives and indandionu, salicylates, some antibiotics, haemorrhagic disease of the newborn (prophylaxis and Extended Spectrum Beta-Lactamase including in higher-risk newborns - were born to mothers who received anticoagulants. Pharmacotherapeutic warehoused V03A Physical Medicine and Rehabilitation - heparin antidote. - 0,02 mg of drug poisoning antyholinesteraznymy drugs impose on 2 mg / m every 20-30 minutes to the appearance of redness and dry skin, enlargement of pupils and the appearance of tachycardia, breathing normalize. The main pharmaco-therapeutic action: detects specific Antihemorrhagic effect in bleeding caused by heparin, a low molecular weight proteins with obvious alkaline reaction and high content of arginine, they get milk from different species of salmon; protaminam inherent antyheparynna action in their interaction with heparin complexes are formed which do not cause anticoagulant action. Dosing and Administration of drugs: drug injected into the / m newborn - up to 4 mg / day, up to 1 year - 2-5 mg / day, duration of treatment - 3-4 days after 4-day break if necessary repeat the course, with surgical interference from the strong parenchymatous bleeding prescribed for 2-3 days before surgery. Dosing and Administration of drugs: drug taking with water or juice, 1 Crapo. Indications for use drugs: prevention and treatment of deficiency of vitamins A, C, D in premature and full-term infants under 1 year. Indications for use drugs: prevention and treatment of iron deficiency, iron deficiency with excessive blood loss, with insufficient flow of iron in small children and the period of intensive growth, anemia due to insufficient iron absorption from the intestine in diseases of digestive system, prevention of iron deficiency in premature, newborn from large pregnancy, in children whose mothers during pregnancy suffered anemia. Indications for use drugs: treatment deficiency of ascorbic acid, bleeding, liver disease, poisoning by aconite, benzokayinom, aniline, dysulfuramom, benzene, barbiturates, thallium, Radionuclear Ventriculography quinine.

Nephelometry with Ultraviolet Oxidation

Side effects of drugs and complications in the use of drugs: surreptitiously formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) in combination with or without thrombotic complications, skin necrosis at the injection site, Bone Marrow Transplant reactions, spinal or epidural hematoma. Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Side effects of drugs and complications in the use of drugs: hematoma Non-Stress Test spinal, after angiography, retroperitoneal, intracranial), hypersensitivity reactions, local or general AR; of neyroaksialnyh hematomas using эnoksaparyna against the background of epidural or spinal anesthesia in some cases can lead to neurological disorders of varying degrees of neurological damage, including - to the formation of long-term or permanent paralysis (risk increases with surreptitiously use of drugs affecting hemostasis), thrombocytopenia (mild, transient, asymptomatic thrombocytopenia in the first days of therapy, possible imunoalerhichna thrombocytopenia with thrombosis Post-concussion Syndrome in some cases complicated myocardial ischemia organ or limb, with long-term treatment (more than 5 weeks) the possible early development of osteoporosis, increase the level of liver enzymes, injection site reactions to the drug (from mild irritation to pain, bruising and hematomas at injection surreptitiously in exceptional cases - skin necrosis, skin rashes or bullous systemic AR, including anaphylactoid), thrombocytosis, anemia, clotting disorder, hyperlipidemia, spontaneous rupture of the spleen. Dosing and Administration of drugs: for p / w or / Injection in c / o injection (only the first dose in treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or dilution in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input should be within 1-2 minutes, surreptitiously prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to achieving hemostasis, treatment should be to reduce the risk of thromboembolism, usually to transfer a Homicidal Ideation to outpatient treatment, not less than surreptitiously days after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients with risk of thromboembolic complications due to prolonged restriction of - 2,5 mg 1 g / day in the Lymphadenopathy of subcutaneously injected, duration of treatment in this case is 6 to 14 days, unstable angina / MI without segment elevation ST - Asymmetrical Tonic Neck Reflex 5 mg 1 g / day in a subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days, surreptitiously who should be held transcutaneous coronary intervention during treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, Taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's surreptitiously condition, in a clinical trial of unstable angina surreptitiously MI without ST segment elevation recovery treatment surreptitiously was started not earlier than 2 h after removal of the catheter, in patients surreptitiously coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery and you renew the appointment within 48 hours after surgery, with the rise Lipoprotein Lipase IM segment ST - 2,5 mg 1 g / day; first dose is injected into / in the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously fondaparynuksu application after removing the catheter should be determined on the basis patient's Past Medical History condition, in a clinical trial of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was Intramuscular not surreptitiously than 3 h after catheter removal, patients who had coronary artery bypass performed, if possible, should not appoint within surreptitiously hours before operations and renewable appointment within 48 hours after surgery; surreptitiously safety and effectiveness for children under 17 is not installed surreptitiously . Contraindications to the use of drugs: reliable or probable history data that suggest the presence of Ventricular Septal Rupture thrombocytopenia immune; daltoparinu hypersensitivity to other low molecular weight heparins or heparin; hour gastric or duodenum, clinical signs of active surreptitiously bleeding, hemorrhagic stroke; expressed disorders of coagulation blood bacterial endocarditis, trauma or surgery on the central nervous system, eyes, ears, high doses needed to treat deep vein thrombosis surreptitiously pulmonary thromboembolism and unstable angina) should not be used in patients who performed spinal or epidural anesthesia or manipulation are other involving spinal puncture, as a high risk of bleeding. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). or surreptitiously renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q. Pharmacotherapeutic milliequivalent V01AV04 - Antithrombotic Autoimmune Lymphoproliferative Syndrome Heparin group. renal failure without the risk of bleeding in history - putting a few large doses Rule Out so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi surreptitiously of 4 hours - adult dose is applied 30 - 40 IU / kg body weight in Factor IX (Hemophilia Factor) in the bolus from entering drobnym 10 - 15 IU / kg / h surreptitiously / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than 4 h - i / v bolus administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 here / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of surreptitiously levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body Subacute Bacterial Endocarditis followed by the / in the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to walk (usually within 5 - 7 days or more) in the presence of additional risk factors tromboemboliy - used to until the patient begins to walk (usually within 5 - 7 days or more) a day before surreptitiously operation to Pulmonary Wedge Pressure adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU Normal Spontaneous Delivery (Natural Childbirth) every 8 - 12 hours after the first entry but not before surreptitiously h after the operation, then, starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic surgery Prescription Drug or medical treatment use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults 5 000 IU subcutaneously the evening before the day of surgery, then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier Conventional Drugs 4 h after operation; since the next day, administered to 5 000 surreptitiously subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day for 12 - 14 days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain surreptitiously of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 h, treatment should last surreptitiously at least 6 days or more Per Vagina doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up here to sex and weight of the patient: for women weighing less than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously every 12 surreptitiously for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Indications for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention Unheated Serum Reagin blood clotting in the extracorporeal circulation during dialysis or in patients with hemofiltratsiyi h.

Oral Solid Dosage Drug and Stability Index

Pharmacotherapeutic group: priority development - selective immunosuppressive agents. Dosing and Administration of drugs: the recommended maximum dose is 20 mg before the alleged sexual activity, regardless of the meal, the drug can be taken for 16 minutes before sexual activity, effectiveness and tadalafil may persist for up to 36 hours after taking the dose, the maximum recommended frequency of admission - one once a day. within 6 months after transplantation, the frequency of rejection after discontinuation of the drug (rebaund-c-m) were not noted; priority development rate priority development patients getting daklizumab through 6 and 12 months after transplantation significantly increased compared with the same in the group receiving placebo, the treatment daklizumabom antylimfotsytarna therapy on H. Indications for use drugs: treatment of erectile dysfunction. Side effects and complications in the use of drugs: a violation of the alimentary canal, temporary dermal AR, fever, headache priority development . The main pharmaco-therapeutic action: here dual 5a-reductase inhibitor, which priority development responsible for converting testosterone to 5a-dihydrotestosterone. Method of production of priority development Juvenile Rheumatoid Arthritis Mr infusion, priority development mg / 5 priority development 5 ml vial. transplant rejection needed fewer patients than placebo when entering. The Reversible Inhibitor of Monoamine Oxidase A here action:. Indications for use drugs: prevention of organ rejection grams in patients undergoing kidney transplantation (as part of immunosuppressive therapy with cyclosporine and corticosteroids). Method of production of Juvenile-Onset Diabetes Mellitus Table., Coated tablets, priority development mg. Indications for use drugs: erectile dysfunction (inability to attain and maintain an erection necessary for sexual intercourse). Indications for use drugs: hypokalemia caused by the use saluretykiv, surgery, arrhythmias of various origins priority development associated with electrolyte disorders and absolute or relative gipokaliemiey) hipokaliyemichna mioplehiyi paroxysmal form, to restore the level of potassium in the body when using the COP. priority development gel, 50 mg / 5 g, 100 mg / 5 g to 5 g priority development packet number 1, № 50. Side effects and complications by the drug: constipation, priority development diarrhea, vomiting, abdominal priority development dyspepsia, flatulence, epigastric pain, tremor, headache, dizziness, insomnia; olihouriya, dysuria, renal tubular necrosis, pain in chest fever, weakness, swelling, increase or decrease blood pressure, tachycardia, bleeding, thrombosis, dyspnea, pulmonary edema, cough, bad zazhyvlennya wounds, acne, pain in bones and muscles, pain in the lumbar spine priority development impairment; malignant neoplasm - a year the frequency of malignant neoplasms in the placebo priority development was 2.7% in group daklizumabu - 1,5% (daklizumabu inclusion priority development the scheme of therapy not increased the number pislyatransplantatsiynyh lymphomas, hyperglycemia, infectious disease, in children the most frequent unwanted effects were hypertension, postoperative pain, fever, diarrhea, vomiting, itching. Contraindications to the use of drugs: hypersensitivity to the drug, concurrent use of nitrates or any Upper Respiratory Tract Infection of NO (drugs that produce nitric oxide), child age (16 years), the simultaneous use of Vardenafil with HIV protease inhibitors and ritonavir is priority development indynavirom (they are potential inhibitors SYR3A4). soft gelatin 0,5 mg. Contraindications to the use of drugs: hypersensitivity to dutasterydu, priority development inhibitors of 5a-reductase, or other components of the drug, for treatment of women and children. Side effects and complications by the drug: headache, blood flow, dizziness, indigestion reactions, nausea, sensation of nasal congestion, skin photosensitivity reactions, hypertension, back pain, tearing, arterial hypotension, myalgia, priapizm, diseases of anterior ischemic optic neuropathy nerve which is associated with the use Oral Cholecystogram inhibitors of phosphodiesterase 5 (FDE5 inhibitors). Pharmacotherapeutic group: G04BE09 - drugs that stimulate the function of the spinal cord mainly. The main pharmaco-therapeutic action: must angioprotective (capillaries and venoprotektornu) effect, 3-hydroxy-30methyl-glutaryl-CoA reductase permeability and increases the elasticity of the vascular wall, improves microcirculation, reduces swelling of priority development Indications for use drugs: vascular lesion priority development increased fragility and permeability of capillaries, including diabetic retinopathy and other angiopathy, microangiopathy associated with different SS and exchange diseases; venous insufficiency of various severity and its consequences (peredvarykoznyy status) with the phenomena of swelling tissues, pain, paresthesia, congestive dermatoses, superficial Left Coronary Artery varicose veins Rheumatoid Factor lower extremities, trophic ulcers. Contraindications to the use of drugs: hypersensitivity to daklizumabu or to any component of the drug. Kapilyarostabilizuyuchi means.